Blog

Jul 10, 2023

Poplar Forest Capital LLC Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Poplar Forest Capital LLC boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 3.0% during the 1st quarter, according to its most recent Form 13F filing with the

Poplar Forest Capital LLC boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 3.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,919 shares of the biotechnology company's stock after acquiring an additional 4,460 shares during the quarter. United Therapeutics accounts for approximately 4.1% of Poplar Forest Capital LLC's investment portfolio, making the stock its 6th biggest holding. Poplar Forest Capital LLC owned approximately 0.33% of United Therapeutics worth $34,472,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. Machina Capital S.A.S. bought a new stake in United Therapeutics during the first quarter worth $45,000. Neo Ivy Capital Management acquired a new position in shares of United Therapeutics in the second quarter valued at $48,000. Global Retirement Partners LLC increased its holdings in shares of United Therapeutics by 198.7% in the first quarter. Global Retirement Partners LLC now owns 224 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 149 shares during the last quarter. Atlas Capital Advisors LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at $51,000. Finally, Archer Investment Corp acquired a new position in shares of United Therapeutics in the first quarter valued at $52,000. 94.08% of the stock is owned by institutional investors.

UTHR traded down $2.74 on Monday, hitting $226.27. 102,845 shares of the stock were exchanged, compared to its average volume of 444,003. United Therapeutics Co. has a 12 month low of $201.65 and a 12 month high of $283.09. The business has a 50-day moving average of $231.18 and a two-hundred day moving average of $228.77. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.68 and a quick ratio of 8.40. The firm has a market capitalization of $10.62 billion, a price-to-earnings ratio of 12.95 and a beta of 0.61.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $5.24 earnings per share for the quarter, topping the consensus estimate of $4.57 by $0.67. United Therapeutics had a net margin of 41.29% and a return on equity of 17.52%. The business had revenue of $596.50 million during the quarter, compared to analysts' expectations of $524.18 million. During the same quarter in the prior year, the business posted $2.41 earnings per share. United Therapeutics's revenue was up 27.8% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Co. will post 18.95 EPS for the current fiscal year.

In other news, EVP Paul A. Mahon sold 6,000 shares of the firm's stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $227.77, for a total value of $1,366,620.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $8,336,154.23. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Paul A. Mahon sold 6,000 shares of the firm's stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $227.77, for a total value of $1,366,620.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $8,336,154.23. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $243.87, for a total transaction of $609,675.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at $8,925,398.13. The disclosure for this sale can be found here. Insiders sold 26,500 shares of company stock valued at $5,939,595 over the last quarter. 12.50% of the stock is owned by company insiders.

Several research firms have commented on UTHR. Morgan Stanley upped their price objective on shares of United Therapeutics from $316.00 to $318.00 and gave the company an "overweight" rating in a report on Thursday, August 3rd. LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $256.00 to $268.00 and gave the company a "buy" rating in a report on Thursday, August 3rd. StockNews.com started coverage on shares of United Therapeutics in a research note on Thursday, August 17th. They issued a "buy" rating on the stock. Wedbush upped their price target on shares of United Therapeutics from $305.00 to $307.00 and gave the company an "outperform" rating in a research note on Thursday, August 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $296.44.

View Our Latest Report on United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.